Meiji Yasuda Asset Management CO Ltd. Neurocrine Biosciences Inc Transaction History
Meiji Yasuda Asset Management CO Ltd.
- $1.95 Billion
- Q2 2025
A detailed history of Meiji Yasuda Asset Management CO Ltd. transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Meiji Yasuda Asset Management CO Ltd. holds 5,793 shares of NBIX stock, worth $807,717. This represents 0.04% of its overall portfolio holdings.
Number of Shares
5,793
Previous 6,892
15.95%
Holding current value
$807,717
Previous $762,000
4.46%
% of portfolio
0.04%
Previous 0.03%
Shares
16 transactions
Others Institutions Holding NBIX
# of Institutions
656Shares Held
101MCall Options Held
290KPut Options Held
214K-
Black Rock Inc. New York, NY14.2MShares$1.98 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.81MShares$1.37 Billion0.02% of portfolio
-
Dodge & Cox San Francisco, CA5.57MShares$776 Million0.42% of portfolio
-
State Street Corp Boston, MA4.47MShares$623 Million0.02% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.09MShares$430 Million0.04% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $13.3B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...